The organizational risks of modern anti-helicobacter pylori therapy
https://doi.org/10.31146/1682-8658-ecg-166-6-29-36
Abstract
Aim: The aim of this work is to assess the organizational risks of H. pylori eradication therapy and the control methods of antibiotic resistance by a clinico-pharmacological analysis of the purchases structure in Russian state-funded medical facilities. Materials and methods: A legal framework in the fields of purchases of products, works, services for state and municipal needs, open contract bids, schedule and annual procurement plans for 2017, the Ministry of Health of Russian Federation statistical materials were explored. Results: According to Russian and international guidelines, current purchases of products, works, services are mainly related to a primary H. pylori identification not its eradication control. “Quasi-reference” H. pylori diagnostic methods with lower sensitivity in comparison to reference ones and extremely low specificity are relatively popular. Conclusion: Information related to the structure of products, works and services purchases for H. pylori diagnostics on the Federal Acts No. 44 and 223 united information web-system (http://zakupki.gov.ru) shows no rational assessment of effective eradication therapy while H. pylori is recognized as a microorganism with a high potential for adverse drug reactions and drug-to-drug adverse interactions development. WHO made H. pylori a priority pathogen for antibiotics research and development.
About the Authors
S. Yu. Serebrova
The Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation (FSBI “SCEEMP” of the Ministry of Health of the Russian Federation); Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
A. B. Prokofiev
The Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation (FSBI “SCEEMP” of the Ministry of Health of the Russian Federation); Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
V. N. Drozdov
Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
N. B. Lazareva
Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
D. O. Kurguzova
Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
M. V. Zhuravleva
The Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation (FSBI “SCEEMP” of the Ministry of Health of the Russian Federation); Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
L. M. Krasnykh
The Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation (FSBI “SCEEMP” of the Ministry of Health of the Russian Federation)
Russian Federation
Russian Federation
G. F. Vasilenko
The Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation (FSBI “SCEEMP” of the Ministry of Health of the Russian Federation)
Russian Federation
Russian Federation
O. V. Dobrovolsky
Federal Budget Organization “Central Clinical Hospital of Civil Aviation”
Russian Federation
Russian Federation
A. K. Starodubtsev
Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
E. N. Kareva
Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Pirogov Russian National Research Medical University (RNRMU)
Russian Federation
Russian Federation
Review
For citations:
Serebrova S.Yu., Prokofiev A.B., Drozdov V.N., Lazareva N.B., Kurguzova D.O., Zhuravleva M.V., Krasnykh L.M., Vasilenko G.F., Dobrovolsky O.V., Starodubtsev A.K., Kareva E.N. The organizational risks of modern anti-helicobacter pylori therapy. Experimental and Clinical Gastroenterology. 2019;(6):29-36. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-166-6-29-36
Views:
253
Email this article 